March Biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials

Source :: Cancer Gene Therapy Week. November 27, 2023, 53
Publication Year :: 2023
Abstract: 2023 NOV 27 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- March Biosciences (March Bio), a clinical stage biotechnology company committed to combating challenging [...]

Subjects :: T cells -- Genetic aspects
Lymphomas -- Genetic aspects
Cancer -- Prevention -- Care and treatment -- Genetic aspects
Biotechnology industry -- Genetic aspects
Clinical trials
Biotechnology industry
Health
Science and technology

Tools